William Ashton Net Worth

The estimated Net Worth of William Ashton is at least $676 Tysiąc dollars as of 21 June 2022. Mr. Ashton owns over 4,283 units of Recro Pharma Inc stock worth over $89,159 and over the last 11 years he sold REPH stock worth over $114,930. In addition, he makes $471,930 as Independent Director at Recro Pharma Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Ashton REPH stock SEC Form 4 insiders trading

William has made over 4 trades of the Recro Pharma Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 4,283 units of REPH stock worth $3,384 on 21 June 2022.

The largest trade he's ever made was selling 9,000 units of Recro Pharma Inc stock on 17 June 2021 worth over $38,160. On average, William trades about 891 units every 39 days since 2014. As of 21 June 2022 he still owns at least 42,660 units of Recro Pharma Inc stock.

You can see the complete history of Mr. Ashton stock trades at the bottom of the page.

William Ashton biography

William (Bill) L. Ashton serves as Independent Director of the Company. Mr. Ashton has been a principal at Harrison Consulting Group, Inc., a privately-held biopharmaceutical consulting firm. From August 2009 to June 2013, Mr. Ashton was the senior vice president of external affairs reporting to the president and an assistant professor at the University of the Sciences in Philadelphia, Pennsylvania. From August 2005 to August 2009, Mr. Ashton was the founding Dean of the Mayes College of Healthcare Business and Policy. Mr. Ashton has 29 years’ experience in the biopharmaceutical industry. From 1989 to 2005, Mr. Ashton held a number of positions at Amgen Inc., a biotechnology company, including vice president of U.S. sales and vice president of commercial and government affairs. Mr. Ashton currently serves on the boards of directors of Spectrum Pharmaceuticals, Inc. and Baudax Bio. He previously served on the board of directors of Galena Biopharma, Inc. from April 2013 until January 2018.

What is the salary of William Ashton?

As the Independent Director of Recro Pharma Inc, the total compensation of William Ashton at Recro Pharma Inc is $471,930. There are 2 executives at Recro Pharma Inc getting paid more, with Geraldine Henwood having the highest compensation of $4,622,980.

How old is William Ashton?

William Ashton is 69, he's been the Independent Director of Recro Pharma Inc since 2009. There are 2 older and 7 younger executives at Recro Pharma Inc. The oldest executive at Recro Pharma Inc is Winston Churchill, 79, who is the Independent Director.

What's William Ashton's mailing address?

William's mailing address filed with the SEC is 2 ATLANTIC AVENUE, , BOSTON, MA, 02110.

Insiders trading at Recro Pharma Inc

Over the last 11 years, insiders at Recro Pharma Inc have traded over $25,533,136 worth of Recro Pharma Inc stock and bought 3,055,820 units worth $22,429,197 . The most active insiders traders include Healthcare Master Fund Ltd ..., Investment Company, Inc. Awm oraz James E Deerfield Mgmt L.P..... On average, Recro Pharma Inc executives and independent directors trade stock every 31 days with the average trade being worth of $151,953. The most recent stock trade was executed by J David Jr Enloe on 15 March 2022, trading 512 units of REPH stock currently worth $1,004.

What does Recro Pharma Inc do?

Recro Pharma Inc. is a contract development and manufacturing organization (CDMO) with capabilities from early feasibility to commercial manufacturing. With an expertise in solving complex manufacturing problems, Recro is a leading CDMO providing oral solid dosage form development, end-to-end regulatory support, clinical and commercial manufacturing, and packaging and logistics services to the global pharmaceutical market.

Complete history of Mr. Ashton stock trades at Recro Pharma Inc, Spectrum Pharmaceuticals oraz Baudax Bio Inc

Recro Pharma Inc executives and stock owners

Recro Pharma Inc executives and other stock owners filed with the SEC include:

• Geraldine Henwood,
  President, Chief Executive Officer, Director
• Ryan Lake,
  Chief Financial Officer
• William Ashton,
  Independent Director
• Wayne Weisman,
  Independent Chairman of the Board
• Winston Churchill,
  Independent Director
• Michael Berelowitz,
  Independent Director
• Ryan D. Lake,
  Chief Financial Officer
• Bryan Reasons,
  Independent Director
• J. David Enloe Jr.,
  Pres, CEO & Director
• Argot Partners,
  IR Contact Officer
• Tim Bourque,
  VP of Operations & Site Head of San Diego
• David Smithwick B.S.,
  VP of Operations & Site Head of Gainesville
• Richard Sidwell Ph.D.,
  VP & Chief Scientific Officer
• Marshall Rizzo M.B.A.,
  Sr. VP & GM
• Randall J. Mack,
  Sr. VP of Devel.
• Erica Raether M.A.,
  VP of People, Culture & ESG
• William Hirschman,
  VP of Sales & Marketing
• Matthew McKendry,
  Director of Accounting
• Laura L. Parks,
  Director
• Karen Flynn,
  Director
• Vitalife Partners Ii Lp Scp,
  10% owner
• Donna Nichols,
  CAO/Controller
• Stewart Mc Callum,
  Chief Medical Officer
• Randall Mack,
  Senior VP, Development
• Fred Graff,
  Chief Commercial Officer
• Capital Management, Llc Sto...,
  10% owner
• James E Deerfield Mgmt L.P....,
  
• Vitalife Partners (Israel) ...,
  10% owner
• Alfred Altomari,
  Director
• Healthcare Master Fund Ltd ...,
  
• Diane Myers,
  Senior VP-Reg./Quality
• Jyrki Mattila,
  Executive VP, Business Dev.
• Michael Celano,
  Chief Financial Officer
• Arnaud Ajdler,
  Director
• Abraham Ludomirski,
  Director
• Charles Garner,
  CFO and Chief Business Officer
• J David Jr Enloe,
  Chief Executive Officer
• James Charles Miller,
  Director
• Investment Company, Inc. Awm,
  10% owner